RBC Capital maintains Johnson & Johnson Outperform rating

0 min read | Published on 09 Jul 2026, 12:31 AM |Updated on 16 Jul 2026, 10:42 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Johnson & Johnson (NYSE:JNJ) and maintained the price target at $287, reflecting a steady valuation outlook.

*this image is generated using AI for illustrative purposes only.

RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Johnson & Johnson (NYSE:JNJ) and maintained the price target at $287. The decision reflects a steady valuation outlook for the healthcare conglomerate.

Rating and Target Details

The price target of $287 remains unchanged. The Outperform rating is sustained, indicating continued confidence in the company's performance.

Metric	Value
Rating	Outperform
Price Target	$287

What specific catalysts could drive Johnson & Johnson's stock to reach the $287 price target?

How might recent regulatory changes impact JNJ's pharmaceutical and medical device segments?

What are the potential risks to JNJ's valuation outlook in the current economic climate?

Wells Fargo raises Johnson & Johnson price target to $272

0 min read | Published on 16 Jul 2026, 10:26 PM |Updated on 16 Jul 2026, 10:26 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Wells Fargo analyst Larry Biegelsen maintained an Overweight rating on Johnson & Johnson (NYSE: JNJ) and raised the price target to $272 from $263, signaling confidence in the stock's performance.

*this image is generated using AI for illustrative purposes only.

Wells Fargo analyst Larry Biegelsen has maintained an Overweight rating on Johnson & Johnson (NYSE: JNJ) while raising the stock's price target to $272 from the previous $263. The adjustment reflects an updated valuation outlook for the healthcare conglomerate.

Rating and Price Target Update

The revised price target of $272 represents an increase from the prior target of $263. The Overweight rating indicates that the analyst expects the stock to outperform the broader market or its sector peers in the near term.